Načítá se...
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
Doxorubicin pharmacokinetics were determined in 33 patients with solid tumours who received intravenous doses of 20–320 mg m(−2) HPMA copolymer bound doxorubicin (PK1) in a phase I study. Since assay constraints limited the data at lower doses, conventional analysis was not feasible and a ‘populatio...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
1999
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2374352/ https://ncbi.nlm.nih.gov/pubmed/10487619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6690657 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|